Product Overview
Structure
Active substance:
Excipients:
Potato starch - 10 mg,
Calcium stearate - 0.65 mg,
Ludipress (composition: lactose monohydrate, povidone (Collidon 30),
crospovidone (Collidone CL)) - to obtain a tablet weighing 100 mg.
pharmachologic effect
The main mechanism of action of Kagocel® is the ability to induce the production of interferons. Kagocel® causes the formation in the human body of the so-called late interferons, which are a mixture of α- and β-interferons with high antiviral activity.
Kagocel® induces the production of interferons in almost all populations of cells participating in the antiviral response of the body: T and B lymphocytes, macrophages, granulocytes, fibroblasts, endothelial cells. When ingesting a single dose of Kagocel®, the serum interferon titer reaches its maximum value after 48 hours.
The interferon response of the body to the administration of Kagocel® is characterized by a prolonged (up to 4-5 days) circulation of interferons in the bloodstream. The dynamics of the accumulation of interferons in the intestine when ingested Kagocel® does not coincide with the dynamics of titers of circulating interferons. In serum, the production of interferons reaches high values ������only 48 hours after taking Kagocel®, while in the intestine, the maximum production of interferons is noted after 4 hours.
Kagocel®, when administered in therapeutic doses, is non-toxic, does not accumulate in the body. The drug does not have mutagenic and teratogenic properties, is not carcinogenic, and does not have an embryotoxic effect.
The greatest effectiveness in the treatment of Kagocel® is achieved when it is prescribed no later than the 4th day from the onset of acute infection. For preventive purposes, the drug can be used at any time, including immediately after contact with an infectious agent.
Pharmacokinetics
24 hours after administration to the body, Kagocel® accumulates mainly in the liver, to a lesser extent in the lungs, thymus, spleen, kidneys, and lymph nodes. Low concentration is noted in adipose tissue, heart, muscles, testes, brain, blood plasma.
The low content of Kagocel® in the brain is explained by the high molecular weight of the drug, which impedes its penetration through the blood-brain barrier. In blood plasma, the drug is predominantly in bound form.
With daily repeated administration of Kagocel®, the volume of distribution varies widely in all the organs examined. The accumulation of the drug in the spleen and lymph nodes is especially pronounced. When taken orally, about 20% of the administered dose of the drug enters the general bloodstream.
The absorbed preparation circulates in the blood, mainly in the form associated with macromolecules: with lipids - 47%, with proteins - 37%. The unbound portion of the drug is about 16%.
Withdrawal
From the body, the drug is excreted mainly through the intestines: after 7 days after administration, 88% of the administered dose is excreted from the body, including 90% through the intestines and 10% by the kidneys. The drug was not found in exhaled air.
Kagocel® induces the production of interferons in almost all populations of cells participating in the antiviral response of the body: T and B lymphocytes, macrophages, granulocytes, fibroblasts, endothelial cells. When ingesting a single dose of Kagocel®, the serum interferon titer reaches its maximum value after 48 hours.
The interferon response of the body to the administration of Kagocel® is characterized by a prolonged (up to 4-5 days) circulation of interferons in the bloodstream. The dynamics of the accumulation of interferons in the intestine when ingested Kagocel® does not coincide with the dynamics of titers of circulating interferons. In serum, the production of interferons reaches high values ������only 48 hours after taking Kagocel®, while in the intestine, the maximum production of interferons is noted after 4 hours.
Kagocel®, when administered in therapeutic doses, is non-toxic, does not accumulate in the body. The drug does not have mutagenic and teratogenic properties, is not carcinogenic, and does not have an embryotoxic effect.
The greatest effectiveness in the treatment of Kagocel® is achieved when it is prescribed no later than the 4th day from the onset of acute infection. For preventive purposes, the drug can be used at any time, including immediately after contact with an infectious agent.
Pharmacokinetics
24 hours after administration to the body, Kagocel® accumulates mainly in the liver, to a lesser extent in the lungs, thymus, spleen, kidneys, and lymph nodes. Low concentration is noted in adipose tissue, heart, muscles, testes, brain, blood plasma.
The low content of Kagocel® in the brain is explained by the high molecular weight of the drug, which impedes its penetration through the blood-brain barrier. In blood plasma, the drug is predominantly in bound form.
With daily repeated administration of Kagocel®, the volume of distribution varies widely in all the organs examined. The accumulation of the drug in the spleen and lymph nodes is especially pronounced. When taken orally, about 20% of the administered dose of the drug enters the general bloodstream.
The absorbed preparation circulates in the blood, mainly in the form associated with macromolecules: with lipids - 47%, with proteins - 37%. The unbound portion of the drug is about 16%.
Withdrawal
From the body, the drug is excreted mainly through the intestines: after 7 days after administration, 88% of the administered dose is excreted from the body, including 90% through the intestines and 10% by the kidneys. The drug was not found in exhaled air.
Indications
Kagocel® is used in adults and children over the age of 3 years as a prophylactic and therapeutic agent for influenza and other acute respiratory viral infections (ARVI), as well as a therapeutic agent for herpes in adults.
Contraindications
- Pregnancy and lactation;
- Age up to 3 years;
- Hypersensitivity to the components of the drug;
- Lactase deficiency, lactose intolerance, glucose-galactose malabsorption.
Side effects
Perhaps the development of allergic reactions.
If any of the side effects indicated in the instructions are aggravated, or if you notice any other side effects not listed in the instructions, inform your doctor.
If any of the side effects indicated in the instructions are aggravated, or if you notice any other side effects not listed in the instructions, inform your doctor.
Interaction
Kagocel® is well combined with other antiviral drugs, immunomodulators and antibiotics (additive effect).
How to take, course of administration and dosage
Inside, regardless of the meal.
For the treatment of influenza and acute respiratory viral infections, adults are prescribed in the first two days - 2 tablets 3 times a day, in the next two days - one tablet 3 times a day. Total for the course - 18 tablets, the duration of the course is 4 days.
Prevention of influenza and SARS in adults is carried out in 7-day cycles: two days - 2 tablets 1 time per day, 5 days off, then repeat the cycle. The duration of the preventive course is from one week to several months.
For the treatment of herpes in adults, 2 tablets are prescribed 3 times a day for 5 days. In total, 30 tablets per course, the duration of the course is 5 days.
For the treatment of influenza and SARS, children aged 3 to 6 years are prescribed in the first two days - 1 tablet 2 times a day, in the next two days - one tablet 1 time per day. In total for the course - 6 tablets, the duration of the course is 4 days.
For the treatment of influenza and SARS, children over the age of 6 are prescribed in the first two days - 1 tablet 3 times a day, in the next two days - one tablet 2 times a day. In total, 10 tablets per course, the duration of the course is 4 days.
Prevention of influenza and SARS in children over the age of 3 years is carried out in 7-day cycles: two days - 1 tablet 1 time per day, 5 days off, then repeat the cycle. The duration of the preventive course is from one week to several months.
For the treatment of influenza and acute respiratory viral infections, adults are prescribed in the first two days - 2 tablets 3 times a day, in the next two days - one tablet 3 times a day. Total for the course - 18 tablets, the duration of the course is 4 days.
Prevention of influenza and SARS in adults is carried out in 7-day cycles: two days - 2 tablets 1 time per day, 5 days off, then repeat the cycle. The duration of the preventive course is from one week to several months.
For the treatment of herpes in adults, 2 tablets are prescribed 3 times a day for 5 days. In total, 30 tablets per course, the duration of the course is 5 days.
For the treatment of influenza and SARS, children aged 3 to 6 years are prescribed in the first two days - 1 tablet 2 times a day, in the next two days - one tablet 1 time per day. In total for the course - 6 tablets, the duration of the course is 4 days.
For the treatment of influenza and SARS, children over the age of 6 are prescribed in the first two days - 1 tablet 3 times a day, in the next two days - one tablet 2 times a day. In total, 10 tablets per course, the duration of the course is 4 days.
Prevention of influenza and SARS in children over the age of 3 years is carried out in 7-day cycles: two days - 1 tablet 1 time per day, 5 days off, then repeat the cycle. The duration of the preventive course is from one week to several months.
Overdose
In case of accidental overdose, it is recommended to prescribe a plentiful drink, cause vomiting.
Special instructions
To achieve a therapeutic effect, Kagocel® should be started no later than the fourth day from the onset of the disease.
Release form
Tablets, round, biconvex, cream color, interspersed.
Storage conditions
In the dark place at a temperature of no higher than 25 C.
Keep out of the reach of children.
Keep out of the reach of children.
Shelf life
4 years.